Jefferies Group lowered shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from a buy rating to a hold rating in a report published on Wednesday morning. Jefferies Group currently has $40.00 target price on the stock, down from their previous target price of $69.00.

Several other research firms have also weighed in on TEVA. Mizuho restated a buy rating and set a $70.00 price objective (down from $75.00) on shares of Teva Pharmaceutical Industries in a research note on Friday, August 5th. Leerink Swann restated an outperform rating and set a $66.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, August 16th. Guggenheim restated a buy rating and set a $80.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Monday, August 15th. JPMorgan Chase & Co. restated an overweight rating and set a $75.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 26th. Finally, Piper Jaffray Cos. restated a neutral rating and set a $57.00 price objective (up from $55.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, August 8th. Thirteen investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of Buy and a consensus price target of $60.00.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up 3.26% on Wednesday, reaching $39.31. 4,680,456 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $42.97 and its 200 day moving average price is $49.87. The company has a market cap of $35.93 billion, a price-to-earnings ratio of 26.26 and a beta of 0.73. Teva Pharmaceutical Industries has a 12 month low of $37.25 and a 12 month high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.02. The company had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.71 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. Teva Pharmaceutical Industries’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.35 EPS. Equities research analysts predict that Teva Pharmaceutical Industries will post $5.16 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is currently 58.39%.

A number of institutional investors have recently made changes to their positions in the stock. Crow Point Partners LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at $169,000. Schafer Cullen Capital Management Inc. boosted its stake in Teva Pharmaceutical Industries by 43.5% in the third quarter. Schafer Cullen Capital Management Inc. now owns 10,565 shares of the company’s stock valued at $486,000 after buying an additional 3,205 shares during the period. Salem Investment Counselors Inc. boosted its stake in Teva Pharmaceutical Industries by 9.5% in the third quarter. Salem Investment Counselors Inc. now owns 6,625 shares of the company’s stock valued at $305,000 after buying an additional 575 shares during the period. Verition Fund Management LLC boosted its stake in Teva Pharmaceutical Industries by 25.3% in the third quarter. Verition Fund Management LLC now owns 36,910 shares of the company’s stock valued at $1,698,000 after buying an additional 7,445 shares during the period. Finally, Highlander Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 87.7% in the third quarter. Highlander Capital Management LLC now owns 19,154 shares of the company’s stock valued at $881,000 after buying an additional 8,950 shares during the period. Hedge funds and other institutional investors own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.